文献速递生殖医学

欧洲人类生殖与胚胎学会不孕症关键研究优先领域:最大化科学、人群与社会影响

ESHRE's key research priorities in infertility: maximizing impact on science, people and society†.
PubMed 文献 · Hum Reprod · 2025-01-01

欧洲人类生殖与胚胎学会(ESHRE)成立多学科工作组,基于指南未来研究建议和特别兴趣小组提案汇总主题,开发影响评分工具并由工作组成员独立评分,最终选出12项不孕症研究优先领域,涵盖预防不孕与生育力保存、妇科疾病、男性不育、优化生育治疗、优化心理社会支持及深化植入前发育与早期妊娠知识六大方面。

要点

  • ESHRE多学科工作组制定12项不孕症研究优先领域,覆盖六大方面。
  • 优先领域基于指南未来研究建议与特别兴趣小组提案汇总主题。
  • 采用新开发影响评分工具评估对个体、社会和科学进步的影响。

核心结论

  • 通过新开发评分工具识别出12项不孕症研究优先领域,大致归入六大方面。

研究设计与样本

  • ESHRE任命多学科工作组(含一名患者代表)制定不孕症相关研究优先领域清单。
  • 研究主题基于ESHRE循证指南中提出的未来研究建议及ESHRE特别兴趣小组作为研究资助征题提交的建议汇总。
  • 开发评分工具评估各主题研究对个体、社会和科学进步的预期影响,由工作组成员独立评分,选出得分最高的12个主题。

主要发现

  • 12项优先领域分布在:预防不孕与生育力保存、妇科疾病、男性不育、优化生育治疗(每领域选2项优先领域)、优化心理社会支持(选1项优先领域)、深化植入前发育与早期妊娠知识(选3项优先领域)。

临床怎么用

  • 本文可激发不孕症研究界对拟议和正在进行研究的潜在影响作进一步思考与讨论。
  • 本文为参与研究资助分配的政策制定者提供信息并鼓励其参考,促进不孕症研究资源更高效、更有目的地分配。

局限性

  • 影响评分工具尚需在未來项目中进一步测试和完善。
  • 部分影响指标的评分在很大程度上基于评分者的判断和专业知识,已通过确保工作组内所有相关学科和主题领域的知识与经验以及患者视角的代表性来加以平衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Which research topics in the area of infertility should be prioritized in the allocation of research resources? SUMMARY ANSWER: Twelve research priorities were formulated, spanning the following areas: preventing infertility and preserving fertility, gynaecological diseases, male infertility, optimizing fertility treatments, optimizing psychosocial support and deepening knowledge on preimplantation development and early pregnancy. WHAT IS KNOWN ALREADY: Many research gaps related to infertility and its management remain understudied and underfunded, making it important to set priorities to ensure appropriate allocation of research resources. STUDY DESIGN, SIZE, DURATION: The European Society of Human Reproduction and Embryology (ESHRE) appointed a multidisciplinary working group, including a patient representative, to develop a list of research priorities related to infertility, which are relevant to researchers and institutions that fund research. PARTICIPANTS/MATERIALS, SETTING, METHODS: A list of research topics was collated based on the recommendations for future research formulated in ESHRE's evidence-based guidelines and suggestions submitted by ESHRE's Special Interest Groups as call topics for the ESHRE research grants. A scoring tool was developed to assess the expected impact of research on each topic on individuals, society and scientific advancement. Topics were scored independently by the working group members and the 12 topics with the highest scores were selected for presentation in this paper. MAIN RESULTS AND THE ROLE OF CHANCE: Using our newly developed scoring tool, we have identified 12 research priorities that broadly fall under six areas. These are preventing infertility and preserving fertility, gynaecological diseases, male infertility, optimizing fertility treatments (two priorities per area selected), optimizing psychosocial support (one priority selected) and deepening knowledge on preimplantation development and early pregnancy (three priorities selected). LIMITATIONS, REASONS FOR CAUTION: The impact scoring tool would benefit from further testing and refinement in future projects. The scoring of some impact indicators is heavily based on the judgment and expertise of the scorers, which was accounted for by ensuring representation of knowledge and experience from all relevant disciplines and subject areas as well as the patient perspective within the working group. WIDER IMPLICATIONS OF THE FINDINGS: This paper may serve to stimulate further thought and discussion within the infertility research community on the potential impact of proposed and ongoing research. It will furthermore inform and encourage policy makers involved in research funding allocation and contribute to a more efficient and purposeful allocation of research resources towards infertility research. STUDY FUNDING/COMPETING INTEREST(S): The technical support for this project was provided by ESHRE. A.C. reports employment at Juno Genetics. Y.C. reports a grant from Guerbet and honoraria from Ferring, Merck, Abbot, Nordic Pharma and Organon. G.C. reports consulting fees from Gedeon Richter and honoraria from Cooper Surgical. S.G. reports the development of www.myjourney.pt licensed under a CC BY-NC-SA 4.0 licence. J.K.-B. reports grants from the NIHR Evaluation and Studies Coordinating Centre, the Gates Foundation, the Economic and Social Research Council, BAYER Consumer Health and MRC Confidence in Concept; honoraria from Ferring and Cooper Surgical; travel support from Ferring, Cooper Surgical, Congressworks LLP, Deutsche Gesellschaft für Andrologie e. V., BAYER, University of Munster and ESHRE; a patent for microchannel sperm cell preparation; and a leadership or fiduciary role in the Association of Clinical and Reproductive Scientists. A.P. reports grants (to her institution) and consulting fees from Gedeon Richter, Ferring, Merck A/S and Cryos; honoraria from Gedeon Richter, Ferring, Merck A/S and Organon; and travel support (to her institution) from Gedeon Richter. H.S.N. reports grants from Freya Biosciences ApS, Ferring Pharmaceuticals, BioInnovation Institute, Ministry of Education, Novo Nordic Foundation, Augustinus Fonden, Oda og Hans Svenningsens Fond, Demant Fonden, Ole Kirks Fond and the Independent Research Fund Denmark; speaker's fees from Ferring, Merck A/S, Astra Zeneca, Cook Medical, Gedeon Richter, Ibsa Nordic, Novo Nordisk A/S; co-development of an app with the Maternity Foundation; and co-founding a project with Lulu Health. The remaining authors (J.T., A.A., I.D., C.F., M.G., A.S.L., M.M.-R., V.N., A.O., N.R., M.S.-L., P.T., N.V., S.V. and K.S.) have nothing to declare. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Tassot J, Ahlstrom A, Capalbo A, et al. ESHRE's key research priorities in infertility: maximizing impact on science, people and society†. Hum Reprod. 2025. PMID: 40796089. doi:10.1093/humrep/deaf150

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。